{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:17:30Z","timestamp":1794889050953,"version":"4.9.1"},"reference-count":52,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of patients with relapsed\/refractory B-cell-derived hematologic malignancies. To date, six CAR T-cell therapies, targeting either CD19 or B-cell maturation antigen, have received regulatory approval. Along with the promising survival benefit, CAR T-cell therapy is associated with potentially life-threatening adverse events, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. While clinical trials evaluating CAR T-cell therapy consistently report the incidence of these adverse events, most trials do not collect health-related quality of life (HRQoL) data. As such, the impact of the CAR T-cell therapy process and related adverse events on the physical and psychological well-being of patients remains uncertain. HRQoL and other patient-reported outcome (PRO) assessments in patients with relapsed or refractory hematologic malignancies are of utmost importance, as individuals may have unmet needs and a high demand for tolerable therapy if a cure is not obtained. In addition, it is important to standardize methods of data collection to better assess the impact of CAR T-cell therapy on quality of life, optimize patients\u2019 care and costs, and enable comparisons between different studies. We conducted a literature search up to June 2023 to identify the HRQoL tools used in clinical trials and in real-world studies investigating CAR T-cell therapy in patients with lymphomas or leukemias. In the present comprehensive review, we summarize the most commonly used CAR T-cell specific and non-specific HRQoL tools and discuss how the use of HRQoL and other PRO tools may be optimized.<\/jats:p>","DOI":"10.3324\/haematol.2022.282363","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T02:10:42Z","timestamp":1709777442000},"page":"2401-2419","source":"Crossref","is-referenced-by-count":9,"title":["Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress"],"prefix":"10.3324","volume":"109","author":[{"given":"Emmanuelle","family":"Tchernonog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Moignet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Anota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Bouguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Rioufol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"64000","doi-asserted-by":"crossref","unstructured":"Mikhael J, Fowler J, Shah N. Chimeric antigen receptor T-cell therapies: barriers and solutions to access. JCO Oncol Pract. 2022; 18(12):800-807.","DOI":"10.1200\/OP.22.00315"},{"key":"64001","doi-asserted-by":"crossref","unstructured":"Chakraborty R, Sidana S, Shah GL, Scordo M, Hamilton BK, Majhail NS. Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities. Biol Blood Marrow Transplant. 2019; 25(5):e155-e162.","DOI":"10.1016\/j.bbmt.2018.11.025"},{"key":"64002","doi-asserted-by":"crossref","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y. CAR-T: what is next?. Cancers (Basel). 2023; 15(3):663.","DOI":"10.3390\/cancers15030663"},{"key":"64003","unstructured":"NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines) - Management of Immunotherapy-Related Toxicities. 2023."},{"key":"64004","doi-asserted-by":"crossref","unstructured":"Cheng R, Scippa K, Locke FL, Snider JT, Jim H. Patient perspectives on health-related quality of life in diffuse large B-cell lymphoma treated with CAR T-cell therapy: a qualitative study. Oncol Ther. 2022; 10(1):123-141.","DOI":"10.1007\/s40487-021-00174-0"},{"key":"64005","doi-asserted-by":"crossref","unstructured":"Wang XS, Srour SA, Whisenant M. Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies. Transplant Cell Ther. 2021; 27(11):930.e1-930.e10.","DOI":"10.1016\/j.jtct.2021.07.007"},{"key":"64006","doi-asserted-by":"crossref","unstructured":"Raymakers AJN, Regier DA, Peacock SJ, Freeman CL. Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials. J Cancer Policy. 2021; 30:100304.","DOI":"10.1016\/j.jcpo.2021.100304"},{"key":"64007","doi-asserted-by":"crossref","unstructured":"Paunescu AC, Copie CB, Malak S. Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study. Ann Hematol. 2022; 101(2):317-332.","DOI":"10.1007\/s00277-021-04689-4"},{"key":"64008","doi-asserted-by":"crossref","unstructured":"Kamal M, Joseph J, Greenbaum U, Hicklen R, Kebriaei P, Srour SA, Wang XS. Patient-reported outcomes for cancer patients with hematological malignancies undergoing chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther. 2021; 27(5):390.e1-390.e7.","DOI":"10.1016\/j.jtct.2021.01.003"},{"key":"64009","doi-asserted-by":"crossref","unstructured":"Efficace F, Vignetti M. Quality of life and CAR-T cell therapy in children, adolescents, and young adults with haematological malignancies. Lancet Oncol. 2019; 20(12):1625-1626.","DOI":"10.1016\/S1470-2045(19)30641-2"},{"key":"64010","doi-asserted-by":"crossref","unstructured":"Mohty M, Minnema MC. Lymphodepleting conditioning regimens. 2022;131-133.","DOI":"10.1007\/978-3-030-94353-0_25"},{"key":"64011","doi-asserted-by":"crossref","unstructured":"Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018; 8(4):539-551.","DOI":"10.1016\/j.apsb.2018.03.001"},{"key":"64012","doi-asserted-by":"crossref","unstructured":"Wang XS, Srour SA, Mendoza T. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. Br J Haematol. 2023; 201(4):738-746.","DOI":"10.1111\/bjh.18677"},{"key":"64013","doi-asserted-by":"crossref","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33(5):337-343.","DOI":"10.3109\/07853890109002087"},{"key":"64014","doi-asserted-by":"crossref","unstructured":"Whisenant MS, Srour SA, Williams LA. The unique symptom burden of patients receiving CAR T-cell therapy. Semin Oncol Nurs. 2021; 37(6):151216.","DOI":"10.1016\/j.soncn.2021.151216"},{"key":"64015","doi-asserted-by":"crossref","unstructured":"Cleeland CS, Mendoza TR, Wang XS. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000; 89(7):1634-1646.","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V"},{"key":"64016","doi-asserted-by":"crossref","unstructured":"Hui D, Bruera E. The Edmonton Symptom Assessment System 25 years later: past, present, and future developments. J Pain Symptom Manage. 2017; 53(3):630-643.","DOI":"10.1016\/j.jpainsymman.2016.10.370"},{"key":"64017","doi-asserted-by":"crossref","unstructured":"Elsawy M, Chavez JC, Avivi I. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood. 2022; 140(21):2248-2260.","DOI":"10.1182\/blood.2022015478"},{"key":"64018","doi-asserted-by":"crossref","unstructured":"Dhawale TM, Johnson PC, Gaballa MR. Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy. Cancer. 2023; 129(3):441-449.","DOI":"10.1002\/cncr.34557"},{"key":"64019","doi-asserted-by":"crossref","unstructured":"Johnson PC, Dhawale T, Newcomb RA. Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2023; 7(14):3541-3550.","DOI":"10.1182\/bloodadvances.2022009117"},{"key":"64020","doi-asserted-by":"crossref","unstructured":"Sidana S, Dueck AC, Thanarajasingam G. Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant. Transplant Cell Ther. 2022; 28(8):473-482.","DOI":"10.1016\/j.jtct.2022.05.004"},{"key":"64021","doi-asserted-by":"crossref","unstructured":"Laetsch TW, Myers GD, Baruchel A. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 2019; 20(12):1710-1718.","DOI":"10.1016\/S1470-2045(19)30493-0"},{"key":"64022","doi-asserted-by":"crossref","unstructured":"Ward J, Smith J, Powers K, Hellsten M, Murray P. Parent psychological distress is associated with symptom burden and health-related quality of life in children and adolescents undergoing stem cell transplantation or chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023; 29(7):462.e1-e9.","DOI":"10.1016\/j.jtct.2023.04.012"},{"key":"64023","doi-asserted-by":"crossref","unstructured":"Reeve BB, McFatrich M, Mack JW. Validity and reliability of the pediatric patient-reported outcomes version of the Common Terminology Criteria for Adverse Events. J Natl Cancer Inst. 2020; 112(11):1143-1152.","DOI":"10.1093\/jnci\/djaa016"},{"key":"64024","doi-asserted-by":"crossref","unstructured":"Knight JM, Szabo A, Arapi I. Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. Commun Med (Lond). 2022; 2(1):49.","DOI":"10.1038\/s43856-022-00116-5"},{"key":"64025","doi-asserted-by":"crossref","unstructured":"Maziarz RT, Waller EK, Jaeger U. Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020; 4(4):629-637.","DOI":"10.1182\/bloodadvances.2019001026"},{"key":"64026","doi-asserted-by":"crossref","unstructured":"Patrick DL, Powers A, Jun MP, Kim Y, Garcia J, Dehner C, Maloney DG. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma. Blood Adv. 2021; 5(8):2245-2255.","DOI":"10.1182\/bloodadvances.2020003503"},{"key":"64027","doi-asserted-by":"crossref","unstructured":"Ruark J, Mullane E, Cleary N. Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2020; 26(1):34-43.","DOI":"10.1016\/j.bbmt.2019.09.037"},{"key":"64028","doi-asserted-by":"crossref","unstructured":"Shah BD, Ghobadi A, Oluwole OO. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021; 398(10299):491-502.","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"64029","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020; 382(14):1331-1342.","DOI":"10.1056\/NEJMoa1914347"},{"key":"64030","doi-asserted-by":"crossref","unstructured":"Gordon LI, Liu FF, Braverman J. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. Haematologica. 2024; 109(3):857-866.","DOI":"10.3324\/haematol.2023.283162"},{"key":"64031","doi-asserted-by":"crossref","unstructured":"Laetsch TW, Maude SL, Rives S. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023; 41(9):1664-1669.","DOI":"10.1200\/JCO.22.00642"},{"key":"64032","doi-asserted-by":"crossref","unstructured":"Abramson JS, Johnston PB, Kamdar M. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Adv. 2022; 6(23):5969-5979.","DOI":"10.1182\/bloodadvances.2022008106"},{"key":"64033","doi-asserted-by":"crossref","unstructured":"Westin JR, Locke FL, Dickinson M. Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed\/refractory large B-cell lymphoma. Clin Cancer Res. 2023; 29(10):1894-1905.","DOI":"10.1158\/1078-0432.CCR-22-3136"},{"key":"64034","doi-asserted-by":"crossref","unstructured":"Barata A, Hoogland AI, Kommalapati A. Change in patients\u2019 perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma. Transplant Cell Ther. 2022; 28(7):401.e1-401.e7.","DOI":"10.1016\/j.jtct.2022.05.015"},{"key":"64035","doi-asserted-by":"crossref","unstructured":"Hoogland AI, Jayani RV, Collier A. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 2021; 10(6):1936-1943.","DOI":"10.1002\/cam4.3664"},{"key":"64036","doi-asserted-by":"crossref","unstructured":"Maillet D, Belin C, Moroni C. Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study. Neuro Oncol. 2021; 23(9):1569-1575.","DOI":"10.1093\/neuonc\/noab077"},{"key":"64037","doi-asserted-by":"crossref","unstructured":"Oswald LB, Li X, Carvajal R. Longitudinal collection of patient-reported outcomes and activity data during CAR-T therapy: feasibility, acceptability, and data visualization. Cancers (Basel). 2022; 14(11):2742.","DOI":"10.3390\/cancers14112742"},{"key":"64038","doi-asserted-by":"crossref","unstructured":"Ram R, Grisariu S, Shargian-Alon L. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study. Haematologica. 2022; 107(5):1111-1118.","DOI":"10.3324\/haematol.2021.278288"},{"key":"64039","doi-asserted-by":"crossref","unstructured":"Akinola IM, Cusatis R, Pasquini MC. Multi-stakeholder qualitative interviews to inform measurement of patient reported outcomes after CAR-T. Transplant Cell Ther. 2023; 29(4):254.e1-254.e9.","DOI":"10.1016\/j.jtct.2023.01.004"},{"key":"64040","doi-asserted-by":"crossref","unstructured":"Stenson CL, Vidrine J, Dewhurst F, Osborne W, Menne T, Stocker R. A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: recommendations for service development and implications for palliative care teams. Palliat Med. 2023; 37(2):215-220.","DOI":"10.1177\/02692163221138880"},{"key":"64041","doi-asserted-by":"crossref","unstructured":"Barata A, Hoogland AI, Hyland KA. Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy. Psychooncology. 2021; 30(8):1294-1301.","DOI":"10.1002\/pon.5674"},{"key":"64042","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba ML, Gordon LI. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"64043","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1):45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"64044","doi-asserted-by":"crossref","unstructured":"Efficace F, Cannella L, Sparano F. Chimeric antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: a scoping review. Hemasphere. 2022; 6(12):e802.","DOI":"10.1097\/HS9.0000000000000802"},{"key":"64045","unstructured":"EuroQol. EQ-5D-5L User Guide. 2019."},{"key":"64046","doi-asserted-by":"crossref","unstructured":"Hays RD, Spritzer KL, Schalet BD, Cella D. PROMIS((R))-29 v2.0 profile physical and mental health summary scores. Qual Life Res. 2018; 27(7):1885-1891.","DOI":"10.1007\/s11136-018-1842-3"},{"key":"64047","doi-asserted-by":"crossref","unstructured":"Aaronson NK, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-376.","DOI":"10.1093\/jnci\/85.5.365"},{"key":"64048","doi-asserted-by":"crossref","unstructured":"Cella DF, Tulsky DS, Gray G. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11(3):570-579.","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"64049","doi-asserted-by":"crossref","unstructured":"Hlubocky FJ, Webster K, Cashy J, Beaumont J, Cella D. The development and validation of a measure of health-related quality of life for non-Hodgkin\u2019s lymphoma: the Functional Assessment of Cancer Therapy\u2014Lymphoma (FACT-Lym). Lymphoma. 2013; 2013:147176.","DOI":"10.1155\/2013\/147176"},{"key":"64050","doi-asserted-by":"crossref","unstructured":"Cocks K, King MT, Velikova G. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012; 48(11):1713-1721.","DOI":"10.1016\/j.ejca.2012.02.059"},{"key":"64051","doi-asserted-by":"crossref","unstructured":"Shah NN, Johnson BD, Schneider D. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020; 26(10):1569-1575.","DOI":"10.1038\/s41591-020-1081-3"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282363\/76736","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282363\/77335","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11501\/76736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:54Z","timestamp":1794045954000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282363","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}